1. Antioxidant Therapy in Acute Central Nervous System Injury: Current State
- Author
-
Ziv Rosenbaum, Yossi Gilgun-Sherki, Daniel Offen, and Eldad Melamed
- Subjects
Programmed cell death ,Necrosis ,Cellular respiration ,Central nervous system ,Biology ,Pharmacology ,Blood–brain barrier ,medicine.disease_cause ,Antioxidants ,Pathogenesis ,medicine ,Animals ,Humans ,Randomized Controlled Trials as Topic ,chemistry.chemical_classification ,Reactive oxygen species ,Brain ,Stroke ,Oxidative Stress ,Treatment Outcome ,medicine.anatomical_structure ,chemistry ,Blood-Brain Barrier ,Acute Disease ,Immunology ,Molecular Medicine ,medicine.symptom ,Reactive Oxygen Species ,Oxidative stress - Abstract
Free radicals are highly reactive molecules generated predominantly during cellular respiration and normal metabolism. Imbalance between cellular production of free radicals and the ability of cells to defend against them is referred to as oxidative stress (OS). OS has been implicated as a potential contributor to the pathogenesis of acute central nervous system (CNS) injury. After brain injury by ischemic or hemorrhagic stroke or trauma, the production of reactive oxygen species (ROS) may increase, sometimes drastically, leading to tissue damage via several different cellular molecular pathways. Radicals can cause damage to cardinal cellular components such as lipids, proteins, and nucleic acids (e.g., DNA), leading to subsequent cell death by modes of necrosis or apoptosis. The damage can become more widespread due to weakened cellular antioxidant defense systems. Moreover, acute brain injury increases the levels of excitotoxic amino acids (such as glutamate), which also produce ROS, thereby promoting parenchymatous destruction. Therefore, treatment with antioxidants may theoretically act to prevent propagation of tissue damage and improve both the survival and neurological outcome. Several such agents of widely varying chemical structures have been investigated as therapeutic agents for acute CNS injury. Although a few of the antioxidants showed some efficacy in animal models or in small clinical studies, these findings have not been supported in comprehensive, controlled trials in patients. Reasons for these equivocal results may include, in part, inappropriate timing of administration or suboptimal drug levels at the target site in CNS. Better understanding of the pathological mechanisms of acute CNS injury would characterize the exact primary targets for drug intervention. Improved antioxidant design should take into consideration the relevant and specific harmful free radical, blood brain barrier (BBB) permeability, dose, and time administration. Novel combinations of drugs providing protection against various types injuries will probably exploit the potential synergistic effects of antioxidants in stroke.
- Published
- 2002
- Full Text
- View/download PDF